How to Lose a Lot of Weight: UK Guide

How to lose a lot of weight safely and sustainably is a question many people in the UK face, and the answer involves far more than willpower alone. Weight management is influenced by biology, behaviour, environment and, in some cases, underlying health conditions. This article outlines realistic expectations for significant weight loss, the most effective evidence-based approaches available in the UK, when to involve your GP, and what NHS and medical options exist, including licensed medicines and bariatric surgery, to help you make informed decisions about your health.

How much weight can you realistically lose, and how quickly?

A realistic rate is 0.5 to 1 kg per week, per NHS guidance; losing 5 to 10 per cent of starting body weight produces measurable improvements in blood pressure, blood glucose and cholesterol.

A realistic and sustainable rate of weight loss for most adults is 0.5 to 1 kg (roughly 1 to 2 lb) per week, in line with NHS guidance. Losing weight more quickly than this is possible in the short term, particularly in the first few weeks of a new eating plan, but rapid early losses often reflect fluid shifts rather than fat reduction. Over time, a steadier pace is associated with better long-term outcomes and a lower risk of nutritional deficiencies.

The total amount of weight a person can lose depends on many factors, including starting weight, age, sex, underlying health conditions, and how consistently lifestyle changes are maintained. Someone with a body mass index (BMI) well above 30 may lose considerably more in absolute terms than someone closer to a healthy weight range, simply because there is more to lose and the metabolic response to a calorie deficit is often greater at higher weights.

It is worth noting that BMI is a useful screening tool but has recognised limitations: it does not account for muscle mass, ethnicity-related differences in risk, or where fat is distributed in the body. Waist circumference is often used alongside BMI in clinical assessments, as recommended in NICE obesity guidance, to give a fuller picture of health risk. Setting a realistic goal, such as losing 5 to 10 per cent of starting body weight, is clinically meaningful and associated with measurable improvements in blood pressure, blood glucose and cholesterol, even before reaching an ideal weight.^[2][4]

What are the most effective ways to lose a lot of weight in the UK?

The most effective approaches combine a moderate calorie deficit with increased physical activity and behavioural support; options include Mediterranean-style eating, lower-carbohydrate diets, total diet replacement programmes and intermittent energy restriction.

The most effective approaches to significant weight loss combine a sustained reduction in calorie intake with increased physical activity, supported by behavioural strategies that address the habits and patterns driving weight gain. No single diet is universally superior, but evidence consistently supports approaches that create a moderate calorie deficit (typically 500 to 600 kcal per day below maintenance needs) while remaining nutritionally complete.

Dietary approaches with good evidence include:

• Mediterranean-style eating, rich in vegetables, wholegrains, legumes, fish and unsaturated fats

• Lower-carbohydrate diets, which some people find easier to sustain and which can improve blood glucose control

• Total diet replacement (TDR) programmes, using nutritionally complete low-calorie products (typically 800 to 900 kcal per day), which NICE recognises as an option for people with type 2 diabetes and obesity; these programmes should be undertaken with clinical supervision, particularly if you take glucose-lowering or other regular medication, as dose adjustments may be needed

• Intermittent energy restriction, such as the 5:2 approach, which suits some individuals better than daily calorie counting

If you are taking glucose-lowering medicines and are considering a significant change to your diet, speak to your GP or diabetes team first, as medication adjustments may be required to avoid hypoglycaemia.

Physical activity supports weight loss and is particularly important for preventing regain. UK Chief Medical Officers' guidelines recommend at least 150 minutes of moderate-intensity activity per week for adults, with strength training on two or more days.^[8][9] Activity alone rarely produces large weight losses without dietary change, but it has independent benefits for cardiovascular health, mental wellbeing and metabolic function.

Behavioural support, whether through a structured group programme, one-to-one counselling or a digital tool, significantly improves adherence. NHS Tier 2 weight management services offer structured, evidence-based programmes and are available via GP referral in many areas of England, though programme content and duration vary by Integrated Care Board (ICB) area.

When should you talk to your GP about losing weight?

Speak to your GP if your BMI is 30 or above (or 27.5 or above for South Asian, Chinese, Black African or Black Caribbean backgrounds), or if you have a weight-related health condition or have been unable to lose weight independently.

You should speak to your GP about weight loss if your BMI is 30 or above, or 27.5 or above if you are from a South Asian, Chinese, Black African or Black Caribbean background, as NICE guidance recognises that these thresholds are associated with increased health risks in these groups. A GP appointment is also appropriate if you have a weight-related health condition such as type 2 diabetes, high blood pressure, sleep apnoea or joint problems, or if you have tried to lose weight independently without success.

Your GP can assess your overall health, identify any underlying conditions that may be contributing to weight gain (such as hypothyroidism or polycystic ovary syndrome), and refer you to appropriate NHS services. They can also review any medications you are taking that may affect weight, such as certain antidepressants, antipsychotics or corticosteroids.

If you have a current or past history of an eating disorder, discuss any planned weight-loss approach with a healthcare professional before starting, to ensure it is appropriate and safe for you.

You should contact your GP promptly if you experience unexplained or unintentional weight loss, as this can occasionally signal an underlying medical condition requiring investigation. Conversely, if you are considering a very low-calorie diet or a significant change to your eating pattern, it is sensible to discuss this with a healthcare professional first, particularly if you have diabetes or take regular medication, as adjustments may be needed.

For non-urgent queries about weight management options, your GP surgery is the right starting point. NHS 111 can provide advice if you have a concern that needs attention sooner but is not an emergency.

NHS-supported options for significant weight loss

The NHS offers a tiered pathway from Tier 2 lifestyle programmes and Tier 3 specialist services through to Tier 4 bariatric surgery, with access and availability varying by Integrated Care Board area.

The NHS offers a structured pathway of weight management support, ranging from community-based lifestyle programmes through to specialist medical and surgical care. Access and availability vary by Integrated Care Board (ICB) area, and your GP or practice nurse can advise on what is commissioned locally.

Tier 2 services provide group or individual lifestyle support, typically including dietary advice, physical activity guidance and behavioural change techniques. Programme content and duration vary by area; many are available free of charge via GP referral in England.

Tier 3 specialist weight management services offer more intensive, multidisciplinary support for people with complex obesity-related conditions. These services may include dietitian input, psychological support, and medical management, and are often a prerequisite for NHS bariatric surgery referral.

Tier 4 services cover specialist bariatric (weight loss) surgery, for people who meet clinical eligibility criteria. These are described further in the section below.

NHS diabetes remission programmes, such as the NHS Type 2 Diabetes Path to Remission Programme, use a structured total diet replacement approach and have demonstrated significant weight loss and diabetes remission rates in eligible participants.

For people who meet specific clinical criteria, NICE technology appraisals have recommended certain licensed weight management medicines (including semaglutide and tirzepatide) for use within specialist NHS services, subject to local ICB commissioning decisions. NHS availability is not automatic and depends on local commissioning.

Bolt Pharmacy is a GPhC-registered UK online pharmacy offering online weight-management consultations, with prescriber review and pharmacist support. Any prescription-only medicine is only considered where clinically appropriate following a consultation, and as a complement to, not a replacement for, NHS pathways.

Are weight loss medicines or surgery right for you?

Weight loss medicines such as semaglutide, tirzepatide and orlistat may be appropriate for adults who meet specific BMI and clinical criteria; bariatric surgery is considered for those with a BMI of 40 or above, or 35 or above with an obesity-related condition.

Weight loss medicines may be appropriate for adults who have not achieved sufficient weight loss through lifestyle changes alone and who meet specific clinical criteria based on BMI and the presence of weight-related health conditions. Currently, medicines licensed in the UK for chronic weight management include:

• Semaglutide injection (Wegovy), available as a subcutaneous injection up to 2.4 mg weekly, with a higher 7.2 mg strength also MHRA-authorised

• Tirzepatide (Mounjaro), a once-weekly injection licensed in the UK for both type 2 diabetes and chronic weight management^[13][14]

• Liraglutide (Saxenda), a once-daily subcutaneous injection

• Oral semaglutide (Wegovy 25 mg tablets), which received MHRA authorisation in June 2026 and is a distinct product from Rybelsus, with its own licensed posology^[16]

• Orlistat, a capsule taken with meals that reduces fat absorption, available on prescription and in lower-dose form from pharmacies

• Orforglipron (Foundayo), an oral GLP-1 receptor agonist that has received regulatory authorisation; availability and commissioning are subject to local decisions^[17][18]

Semaglutide and liraglutide act as GLP-1 receptor agonists, mimicking gut hormones that regulate appetite and food intake. Tirzepatide is a dual GIP and GLP-1 receptor agonist, acting on two complementary hormone pathways. All of these injectable and oral GLP-1-based medicines are intended to be used alongside a reduced-calorie diet and increased physical activity, not as a replacement for lifestyle change.

Common side effects of GLP-1-based medicines include nausea, vomiting, diarrhoea and constipation, particularly during dose escalation. The UK SmPCs for this medicine class advise that acute pancreatitis has been reported, including post-marketing reports of necrotising pancreatitis and reports with a fatal outcome; patients should be aware of the symptoms (such as severe and persistent abdominal pain, sometimes radiating to the back) and seek medical advice promptly if they occur.^[19][14] Gallbladder problems, including gallstones and cholecystitis, have also been reported with this medicine class; seek medical review if you develop persistent upper abdominal pain, fever or jaundice. People with pre-existing diabetic retinopathy who use GLP-1-based therapies should discuss monitoring with their prescriber, as worsening of retinopathy has been reported in some individuals.

These medicines are not recommended during pregnancy or breastfeeding. If you are planning a pregnancy, discuss this with your prescriber in advance, as a washout period before conception may be advised depending on the specific medicine. Effective contraception is important during treatment.

For tirzepatide (Mounjaro) specifically, the UK SmPC advises using an additional non-oral contraceptive method for four weeks after starting treatment and for four weeks after each dose increase, because tirzepatide may reduce the effectiveness of oral contraceptives during this period.

If you experience a suspected side effect from any weight management medicine, you can report it to the MHRA via the Yellow Card scheme at yellowcard.mhra.gov.uk.

Bariatric surgery (such as gastric bypass or sleeve gastrectomy) is considered for people with a BMI of 40 or above, or 35 or above with a significant obesity-related condition, in line with NICE guidance. NICE also recognises lower BMI thresholds for people with recent-onset type 2 diabetes, and ethnic-specific adjustments apply for some groups. Surgery produces the largest and most durable weight losses but carries surgical risks and requires lifelong dietary and nutritional follow-up. A thorough assessment by a multidisciplinary team is essential before any surgical decision is made.

How do you keep the weight off once you have lost it?

Sustained physical activity, continued dietary habits, regular self-monitoring and ongoing behavioural support offer the strongest evidence for long-term weight maintenance after significant loss.

Maintaining weight loss long term is often harder than losing the weight in the first place, because the body adapts to a lower weight by reducing its resting metabolic rate and increasing appetite-driving hormones, a process sometimes called metabolic adaptation. Understanding this biological reality helps set realistic expectations and underscores why ongoing support matters.

Strategies with the strongest evidence for weight maintenance include:

• Continuing regular physical activity, with evidence suggesting that higher activity levels (around 200 to 300 minutes per week) are associated with better maintenance than the minimum recommended for general health

• Maintaining dietary habits established during the weight loss phase, rather than returning to previous patterns once a target is reached

• Regular self-monitoring, such as weekly weighing, which allows early identification of gradual regain before it becomes significant

• Ongoing behavioural support, whether through a maintenance programme, peer group or digital tool

For people who have lost weight with the help of a licensed medicine, clinical evidence (including randomised trial data from the semaglutide STEP extension and the tirzepatide SURMOUNT-4 study) indicates that stopping the medicine is associated with gradual weight regain in many cases. Decisions about how long to continue treatment should be made in discussion with a prescriber, taking into account clinical benefit, tolerability and individual circumstances. Planned long-term follow-up with your GP or weight management service is an important part of sustaining results.

If weight begins to return despite sustained effort, this is not a personal failing but a signal that additional support may be needed. Returning to your GP or weight management service for a review is a constructive step, and there is no clinical reason to wait until significant regain has occurred before seeking help. Long-term weight management is best understood as an ongoing process rather than a fixed endpoint.

Scientific References

1. Tips to help you lose weight.
2. Overweight and obesity management (NG246).
3. Overweight and obesity management (NG246) – Medicines and surgery chapter.
4. Overweight and obesity management (NG246) – full guideline PDF.
5. NG246 Appendix A1: Summary of evidence from surveillance (ethnicity-specific BMI thresholds).
6. NG246 Appendix C review protocols – very-low-calorie diet (total diet replacement).
7. Overweight and obesity in adults.
8. UK Chief Medical Officers' physical activity guidelines.
9. Physical activity guidelines for adults aged 19 to 64.
10. Single-dose 7.2 mg semaglutide (Wegovy) pen approved to treat adult patients with obesity.
11. Medicines regulator approves up to 7.2 mg dose of semaglutide (Wegovy) for patients with obesity only.
12. Wegovy – European Medicines Agency EPAR.
13. MHRA authorises diabetes drug Mounjaro (tirzepatide) for weight management and weight loss.
14. Mounjaro KwikPen SmPC (EMC).
15. Tirzepatide – BNF drug monograph.
16. First GLP-1 tablet for weight loss approved in the UK (oral semaglutide/Wegovy 25 mg tablets).
17. UK first in Europe to authorise orforglipron (Foundayo) for weight management and type 2 diabetes.
18. New oral GLP-1 medicine for weight management and type 2 diabetes (Foundayo/orforglipron).
19. GLP-1 receptor agonists and dual GLP-1/GIP receptor agonists: strengthened warnings on acute pancreatitis including necrotising and fatal cases.
20. Semaglutide (Wegovy, Ozempic, Rybelsus): risk of non-arteritic anterior ischaemic optic neuropathy (NAION).
21. Semaglutide, reduction in glycated haemoglobin and the risk of diabetic retinopathy. Diabetes Obes Metab. 2018..
22. Semaglutide – eye-catching results. World J Diabetes. 2023..
23. Ocular complications from GLP-1 receptor agonists: clinical evidence, potential mechanisms, and clinical recommendations. J Chin Med Assoc. 2025..
24. Women on 'skinny jabs' must use effective contraception – MHRA urges in latest guidance (Mounjaro/tirzepatide).
25. Non-invasive weight loss procedure can be an option to treat obesity.
26. Wilding JPH et al. Weight regain and cardiometabolic effects after withdrawal of semaglutide (STEP 1 extension). Lancet. 2022..
27. Aronne LJ et al. The SURMOUNT-4 Randomized Clinical Trial (tirzepatide withdrawal and weight regain). JAMA. 2024..
28. Horn DB et al. Cardiometabolic parameter change by weight regain on tirzepatide withdrawal (SURMOUNT-4). JAMA Intern Med. 2026..
29. Budini B et al. Trajectory of weight regain after cessation of GLP-1 receptor agonists. EClinicalMedicine. 2026..

Frequently Asked Questions